The company is being added to the S&P 600 Index.
News & Analysis: SciClone Pharmaceuticals
Rising demand in China is leading to greater sales of the company's hepatitis B medication.
SciClone Pharmaceuticals, Inc shares jump as sales of Zadaxin climb.
The company taps veteran finance executive Wilson Cheung for the the job.
The pharmaceutical company's bottom line drops by nearly $10 million.
The "China-centric" pharmaceutical aims to correct accounting errors.
This U.S.-based seller of licensed drugs in China had a tough quarter.
And one more that isn't.
A quick look at some notable health care movers.
Market-trouncing returns could be written in this 4-Star.